XORTX Therapeutics Inc. (NASDAQ:XRTX – Get Free Report) saw a significant growth in short interest in the month of October. As of October 15th, there was short interest totaling 237,048 shares, a growth of 285.2% from the September 30th total of 61,535 shares. Currently, 14.0% of the company’s shares are sold short. Based on an average daily trading volume, of 2,819,981 shares, the days-to-cover ratio is presently 0.1 days.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of XORTX Therapeutics in a research report on Monday, September 21st. One research analyst has rated the stock with a Sell rating. According to MarketBeat.com, XORTX Therapeutics currently has an average rating of “Sell”.
Get Our Latest Analysis on XRTX
XORTX Therapeutics Trading Up 3.8%
XRTX opened at $1.10 on Wednesday. The firm has a market cap of $2.00 million, a price-to-earnings ratio of -0.40 and a beta of 0.78. XORTX Therapeutics has a 12 month low of $0.83 and a 12 month high of $3.65. The stock has a fifty day moving average price of $1.79 and a 200-day moving average price of $2.16.
XORTX Therapeutics (NASDAQ:XRTX – Get Free Report) last posted its earnings results on Saturday, August 15th. The technology company reported ($1.05) earnings per share (EPS) for the quarter.
XORTX Therapeutics Company Profile
XORTX Therapeutics Inc (NASDAQ:XRTX) is a clinical-stage pharmaceutical company focused on developing therapies for conditions associated with dysregulated uric acid metabolism. The company’s research is centered on inhibiting xanthine oxidase, an enzyme involved in uric acid production, with the goal of addressing kidney and other serious chronic diseases.
XORTX’s development programs include XRx-008, an orally administered therapy being developed for autosomal dominant polycystic kidney disease, a genetic disorder that can progressively impair kidney function.
See Also
- Five stocks we like better than XORTX Therapeutics
- Taiwan Semiconductor Flexes Pricing Power on AI’s Frontline
- Hidden in Plain Sight: 2 Earnings Winners Investors May Have Missed
- These 3 New ETFs Are Turning Heads—Are They Worth Buying?
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
Receive News & Ratings for XORTX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XORTX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
